Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole

Summary

The intra-cellular uptake of the weakly basic radiosensitiser pimonidazole (PIMO) was determined as a function of the pigmentation of Na11+human melanotic melanoma cells in vitro. Two experimental conditions were considered: exponentially growing cells (Exp.) and plateau-phase cells (PI). The melanin content of Na11+cells ranged from 500 μg/g cell weight in exponentially growing cells to 6000 μg/g in heavily pigmented plateauphase cells. Cells were exposed to PIMO (medium dose, 0.2 mmol/dm³; 58.2 μg/ml). The intra-cellular concentration ranged from 163 μg/g in Exp. to 900 μg/g in pigmented Pl.; the latter being equivalent to an intra-to extracellular concentration ratio (Ci/Ce) of 17. However, this increase in the cellular uptake of PIMO was not accompanied by an increase in radiosensitising efficiency. In comparison, the Ci/Ce for etanidazole (ETA), a radiosensitiser that is uncharged at physiological pH, remained approximately constant at 1 for all values of melanin contents. Treatment of Na11+tumours in vivo with [³H]-PIMO resulted in a tumour: blood ratio of about 3 at 30–60 min after administration. However, at 24 h a grain count of label derived from [³H]-PIMO showed that picnotic areas of tumours contained levels that were some 40 times greater than the background value. This high level of label was coincident with areas of highest apparent melanin content. In conclusion, PIMO accumulates in very heavily pigmented melanoma cells present in necrotic zones with picnosis. As these cells are probably non-clonogenic, PIMO is not suitable for use in melanoma radiotherapy.